SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Add as a preferred source on Google
BOSTON, Feb. 20, 2018 -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that Joan Mannick, M.D., Chief Medical Officer, will present a company overview at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22, 2018 at 2:05 p.m. ET in New York.
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging.
Contacts:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Michael Lampe
Scient PR
484-575-5040
[email protected]
